Search results
Results from the WOW.Com Content Network
427 FTE (2018/19) Website. www.healthcareimprovementscotland.org. Healthcare Improvement Scotland (HIS) (Scottish Gaelic: Leasachadh Cùram Slàinte na h-Alba) is the national healthcare improvement organisation for Scotland. It is a public body which is part of the Scottish National Health Service, created in April 2011.
The new definition also allows the Scottish Medicines Consortium (SMC) the ability to treat some medicines for rare orphan diseases as ultra-orphan medicines. The changes mean if the medicine meets the new definition of an ultra-orphan medicine and the SMC consider it clinically effective, then it will be made available on the NHS for at least ...
Eisai and Biogen said they are working with NICE, the Scottish Medicines Consortium and the National Health Service to make Leqembi available “as soon as possible.” Shares of Biogen were down ...
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR -positive and HER2 -negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. [5][6] Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.
Nestlé Clinical – Nestlé Clinical Nutrition. Neutrogena – Johnson & Johnson Ltd. Novartis – Novartis Pharmaceuticals UK Ltd. Novartis Consumer Health – Novartis Consumer Healththcare. Novo Nordisk – Novo Nordisk Ltd. Nycomed – Nycomed UK Ltd. Octapharma – Octapharma Ltd. Oral B Labs – Oral B Laboratories Ltd.
In Scotland, the Scottish Medicines Consortium advises NHS Boards there about all newly licensed medicines and formulations of existing medicines as well as the use of antimicrobiotics but does not assess vaccines, branded generics, non-prescription-only medicines (POMs), blood products and substitutes or diagnostic drugs. Some new drugs are ...
In 2013/4 the Scottish Medicines Consortium (SMC) approved nalmefene for use as part of the NHS National Services Scotland. [2] Some studies have shown the treatment to be effective in reducing the urge to drink.
Trastuzumab deruxtecan is indicated for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting and for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal ...